VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 78 filers reported holding VAXCYTE INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,224,611 | -6.8% | 82,868 | -8.7% | 0.01% | 0.0% |
Q2 2023 | $4,534,202 | +60.8% | 90,793 | +20.7% | 0.01% | +50.0% |
Q1 2023 | $2,820,407 | -20.4% | 75,251 | +1.8% | 0.00% | -33.3% |
Q4 2022 | $3,543,313 | +187.4% | 73,896 | +43.8% | 0.01% | +200.0% |
Q3 2022 | $1,233,000 | +10.6% | 51,377 | +0.3% | 0.00% | 0.0% |
Q2 2022 | $1,115,000 | +27.1% | 51,237 | +41.1% | 0.00% | +100.0% |
Q1 2022 | $877,000 | -6.6% | 36,314 | -8.0% | 0.00% | 0.0% |
Q4 2021 | $939,000 | -3.2% | 39,465 | +3.2% | 0.00% | 0.0% |
Q3 2021 | $970,000 | -21.3% | 38,238 | -30.2% | 0.00% | -50.0% |
Q2 2021 | $1,233,000 | +42.9% | 54,790 | +25.4% | 0.00% | +100.0% |
Q1 2021 | $863,000 | +17.9% | 43,698 | +58.6% | 0.00% | 0.0% |
Q4 2020 | $732,000 | -46.2% | 27,559 | 0.0% | 0.00% | -50.0% |
Q3 2020 | $1,361,000 | – | 27,559 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |